SKEL’s Involvement in the EFTA Surveillance Authority Inquiry
SKEL fjárfestingafélag hf, known as SKEL, is currently under the scrutiny of the EFTA Surveillance Authority (ESA). This inspection comes as part of an investigation regarding Lyfjaval ehf, which is subject to ESA's regulatory oversight. The inspection is mandated by legal requirements outlined in Article 20, paragraph 4, of the Protocol relating to the EFTA.
Understanding the Investigation Dynamics
Lyfjaval is owned by Heimkaup ehf, which has an 81% ownership stake held by SKEL and its associated companies. The ESA's inquiry primarily focuses on the retail pharmaceutical market, particularly examining allegations related to the operations of traditional versus drive-through pharmacies. Specifically, it is claimed that Lyfjaval has shut down a traditional pharmacy in Mjódd to emphasize its drive-through services.
SKEL’s Market Position and Recent Developments
According to estimates by SKEL, Lyfjaval commands around 10% of the market share within this sector. The involvement of SKEL in Lyfjaval deepens, as it partially acquired the organization on June 25, 2021, with the full acquisition completed by March 29, 2023. Currently, SKEL and its subsidiaries manage seven pharmacies, with five of them operating as drive-through pharmacies that also serve as traditional pharmacies for customer convenience. Noteworthy is the opening of three new pharmacies since 2022, reflecting the company's growth in this sector.
The Nature of the Inquiry
The ESA's investigation spans a transaction in which Lyfjaval sold commercial premises to Lyf og Heilsa, finalized under an agreement on April 26, 2022. The Competition Authority was informed about this transaction and subsequently closed it, issuing decision no. 1/2023 on March 2, 2023. However, this decision was appealed to the Competition Appeals Committee, culminating in a ruling on August 9, 2023.
Cooperation and Commitment to Fair Practices
SKEL has expressed its dedication to collaborating with the ESA throughout this inquiry. The company has proactively provided all requested information, reflecting its commitment to transparency. Furthermore, SKEL remains confident that no competitive laws have been transgressed in Lyfjaval's operational activities, ensuring compliance with all relevant regulations.
Contact Information for Further Inquiries
For any additional details or inquiries regarding this matter, stakeholders can reach out to Ásgeir Helgi Reykfjörður, who serves as the CEO of SKEL. Queries can be sent via email to fjarfestar@skel.is.
Frequently Asked Questions
What is the ESA investigation about?
The ESA investigation focuses on Lyfjaval's operations and potential market segmentation in the retail pharmaceutical sector.
How is SKEL related to Lyfjaval?
SKEL holds an 81% ownership stake in Heimkaup, which owns Lyfjaval, thus having a significant influence over its operations.
What pharmacies does SKEL operate?
SKEL currently operates seven pharmacies, five of which are drive-through facilities that also serve traditional pharmacy customers.
What was the outcome of the Competition Authority's involvement?
The Competition Authority closed its investigation related to a transaction involving Lyfjaval but the decision was appealed, leading to further examination.
Who can be contacted for more information regarding SKEL?
Ásgeir Helgi Reykfjörður, the CEO of SKEL, is the primary contact for further inquiries.
